Proteins for In-Vitro Diagnostic Tests

Serological testing for antibodies directed against SARS-CoV-2 in patients may serve as diagnostic tool to verify a previous infection and as surrogate for an elicited humoral immune response, ideally conferring immunity after infection or vaccination. Together with Bühlmann Laboratories AG, we have developed a unique rapid immuno-assay to detect the presence of RBD binding antibodies with high sensitivity and specificity. As currently available vaccines focus on the Spike RBD as target, the developed test can also be used to monitor a successful immune response after vaccination with an RBD based vaccine.

Click here to learn more:

Development of a unique rapid test to detect antibodies directed against an extended RBD of SARS-CoV-2 spike protein

Larissa Brosi, Eric Kübler, Anna Weston, Patrick Romann, Sherin Panikulam, Lorin Dirscherl, Michael Gerspach, Cedric Giegelmann, Daniele Dolce, Marie-Eve Überschlag, Anna Melone, Frank I Bantleon, Thomas K Villiger, Christian-B Gerhold, CHIMIA (2021)

×